<DOC>
	<DOC>NCT01848925</DOC>
	<brief_summary>The purpose of this study is to compare the safety of SANGUINATE™ versus Hydroxyurea in patients suffering from Sickle Cell Disease.</brief_summary>
	<brief_title>Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients</brief_title>
	<detailed_description />
	<mesh_term>Anemia, Sickle Cell</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Patients with Homozygous (HbSS) Sickle Cell Anemia; Hb levels: &gt;6g/dL &lt;10g/dL; Age : &gt;18 years old; Frequency of ER hospitalizations &lt; 6x/yr for SCD pain events documented "medical history". Patients, who are on chronic transfusion program, defined as regular transfusions every 28 weeks; Allergic to Hydroxyurea; History of clinical significant disease, as determined by the Investigator; History of allergy or major allergic reaction considered to be clinically significant by the Investigator; Screening assessments considered to be abnormal by the Investigator; Patient has sever pulmonary hypertension (index &gt;3 meters per sec); Donated blood within 60 days of screening or otherwise experienced blood loss of &gt;250 mL within the same period; Intending to begin new concomitant drug therapy or overthecounter medication anytime from scree4nin to the time of administration of study drug;</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>SANGUINATE</keyword>
</DOC>